Evidence map›Paper›PMID 36325756›Full record

ArticleACS infectious diseases2022

1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in

Vinayak Singh, Anna E Grzegorzewicz, Stephen Fienberg, Rudolf Müller, Lutete Peguy Khonde, Olalla Sanz, Salvatore Alfonso, Beatriz Urones, Gerard Drewes, Marcus Bantscheff and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Vinayak SinghDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.ORCID 0000-0001-9002-2489
Anna E GrzegorzewiczMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado80523-1682, United States.
Stephen FienbergDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.
Rudolf MüllerDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.
Lutete Peguy KhondeDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.
Olalla SanzGlobal Health Pharma Research Unit, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid28760, Spain.
Salvatore AlfonsoGlobal Health Pharma Research Unit, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid28760, Spain.
Beatriz UronesGlobal Health Pharma Research Unit, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, Madrid28760, Spain.
Gerard DrewesCellzome GmbH · A GSK Company, Meyerhofstrasse 1, Heidelberg69117, Germany.
Marcus BantscheffCellzome GmbH · A GSK Company, Meyerhofstrasse 1, Heidelberg69117, Germany.ORCID 0000-0002-8343-8977
Sonja Ghidelli-DisseCellzome GmbH · A GSK Company, Meyerhofstrasse 1, Heidelberg69117, Germany.
Thomas R IoergerDepartment of Computer Science and Engineering, Texas A&M University, College Station, Texas77843, United States.
Bhanupriya AngalaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado80523-1682, United States.
Jiuyu LiuDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee38105, United States.
Richard E LeeDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee38105, United States.ORCID 0000-0002-2397-0443
James C SacchettiniTexas A&M University, Department of Biochemistry and Biophysics, ILSB 2138, 301 Old Main Dr, College Station, Texas77843-3474, United States.ORCID 0000-0001-5767-2367
Inna V KriegerTexas A&M University, Department of Biochemistry and Biophysics, ILSB 2138, 301 Old Main Dr, College Station, Texas77843-3474, United States.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado80523-1682, United States.ORCID 0000-0002-9212-0258
Kelly ChibaleDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.ORCID 0000-0002-1327-4727
Sandeep R GhorpadeDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch7701, South Africa.ORCID 0000-0002-9311-1572
University of Cape Town · ZAColorado State University · USGlaxoSmithKline (Spain) · ESTexas A&M University · USSouth African Medical Research Council · ZASt. Jude Children's Research Hospital · US

Funding

Vulnerabilities in Mycobacterial Cell-Wall BiogenesisP01AI095208 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SACCHETTINI, JAMES C · 2012 to 2022
$19.8M
Mechanisms of Susceptibility and Resistance of Mycobacterium tuberculosis to Isoxyl and ThiacetazoneR21AI130929 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2017 to 2018
$442k
Inhibitors of Mycobacterium tuberculosis FAS-II dehydratasesR21AI153477 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2020 to 2021
$376k
NIAID NIH HHS P01 AI095208NIAID NIH HHS R21 AI130929NIAID NIH HHS R21 AI153477
6 · The paper itself

Abstract

Alternative mode-of-inhibition of clinically validated targets is an effective strategy for circumventing existing clinical drug resistance. Herein, we report 1,3-diarylpyrazolyl-acylsulfonamides as potent inhibitors of HadAB/BC, a 3-hydroxyl-ACP dehydratase complex required to iteratively elongate the meromycolate chain of mycolic acids in

Indexed as

Mycobacterium tuberculosisThioacetazoneBacterial ProteinsHydro-LyasesMycolic AcidsBacterial ProteinsHydro-LyasesMycolic AcidsThioacetazone1,3-diarylpyrazolyl-acylsulfonamides3-hydroxyl-ACP dehydrataseFASII pathwayMycobacterium tuberculosistuberculosis drug discovery

Identifiers

PMID36325756
PMCPMC9673142
OpenAlexW4308255011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.